Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 712
- Registration Number
- NCT03088540
- Locations
- 🇺🇦
Clinical Study Site 2, Kyiv, Ukraine
🇹🇷Clinical Study Site 3, İzmir, Turkey
🇧🇷Clinical Study Site #3, São Paulo, Brazil
A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Conditions
- Recurrent Adult Acute Myeloid LeukemiaRecurrent Anaplastic Large Cell LymphomaB-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic SyndromeRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Plasma Cell MyelomaPreviously Treated Myelodysplastic SyndromeRecurrent T-Cell Non-Hodgkin LymphomaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Positron Emission TomographyDrug: CyclophosphamideBiological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterProcedure: Single Photon Emission Computed TomographyDrug: RuxolitinibBiological: Cemiplimab
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT03017820
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 333
- Registration Number
- NCT03005782
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸California Pacific Medical Center (CPMC), San Francisco, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 432
- Registration Number
- NCT02760498
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸University of Arizona Cancer Center, Phoenix, Arizona, United States
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02651662
- Locations
- 🇦🇹
Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III, Salzburg, Austria
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇺🇸University of California Los Angeles Medical Center, Santa Monica, California, United States
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 398
- Registration Number
- NCT02383212
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Conditions
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: MK-2206 with or without TrastuzumabDrug: T-DM1 and PertuzumabDrug: Pertuzumab and TrastuzumabDrug: GanetespibDrug: ABT-888Drug: NeratinibDrug: PLX3397Drug: Pembrolizumab - 4 cycleDrug: Talazoparib plus IrinotecanDrug: Patritumab and TrastuzumabDrug: Pembrolizumab - 8 cycleDrug: SGN-LIV1ADrug: Durvalumab plus OlaparibDrug: SD-101 + PembrolizumabDrug: Tucatinib plus trastuzumab and pertuzumabDrug: CemiplimabDrug: Cemiplimab plus REGN3767Drug: Trilaciclib with or without trastuzumab + pertuzumabDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Dan222 + NiraparibDrug: Sarilumab + Cemiplimab + PaclitaxelDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: AmcenestrantDrug: Amcenestrant + AbemaciclibDrug: Amcenestrant + LetrozoleDrug: ARX788Drug: ARX788 + CemiplimabDrug: VV1 + CemiplimabDrug: Datopotamab deruxtecanDrug: Datopotamab deruxtecan + DurvalumabDrug: ZanidatamabDrug: LasofoxifeneDrug: Z-endoxifenDrug: ARV-471Drug: ARV-471 + LetrozoleDrug: ARV-471 + AbemaciclibDrug: Endoxifen + AbemaciclibDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kansas, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.